Latest news
Prevention Is Now Alzheimer’s Hardest Trial
Roche’s PrevenTRON trial moves trontinemab into cognitively unimpaired people at high biological risk of Alzheimer’s decline. The science is bold. The ethics and access questions are even bigger.
Menopause is a cardiometabolic checkpoint. Health systems still treat it like a hormone debate
China’s Biliary-Cancer Bet Has a Global Access Problem
Alzheimer’s Trials Are Finally Blood-Gated
MS Regulators Are No Longer Reading the Same Risk
NTDs Are Now A Human-Rights Issue. Budgets Must Follow.
Europe Can Forecast Vibrio Risk. It Still Has To Act.
Cardiology has too many dashboards. The danger is forgetting the patient
GLP-1 drug choice now affects cardiovascular outcomes. Access and reimbursement rules have not caught up
A CE Mark Is Not Access
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.